Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a pioneering biopharmaceutical company focused on the development of innovative antiviral therapeutics. Led by a team of experienced professionals, Chimerix aims to enhance the quality of life for patients across diverse medical fields, including transplant, oncology, acute care, and global health.
Chimerix leverages its proprietary lipid technology, resulting in two promising clinical-stage compounds: CMX001 and CMX157. These compounds have shown potential for improved activity, bioavailability, and safety over existing drugs. The lead compound, CMX001, is a broad-spectrum antiviral that combats double-stranded DNA (dsDNA) viruses, such as cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus, and variola (smallpox). CMX001 has completed Phase 2 development for CMV prophylaxis and is currently in Phase 2 trials for adenovirus treatment in hematopoietic stem cell transplant (HSCT) recipients.
Chimerix’s portfolio also includes ONC201, an oral, first-in-class small molecule imipridone targeting H3 K27M-mutant gliomas. The Phase 3 ACTION trial for ONC201 is a major focus, enrolling patients at over 130 sites in 13 countries. This study aims to report interim overall survival data by early 2025. Additionally, Chimerix's second-generation compound, ONC206, is undergoing Phase I dose escalation trials, demonstrating anti-cancer activity in both CNS and non-CNS tumors.
Financially, Chimerix maintains a robust balance sheet with significant capital to fund ongoing operations, reflecting sound fiscal management. The company reported a net loss of $18.6 million for Q2 2023 but continues to advance its research and development initiatives.
Chimerix’s mission is to develop medications that significantly improve and extend the lives of patients battling severe diseases. With ongoing clinical trials, strategic financial planning, and a dedicated team, Chimerix is poised to make substantial contributions to global health.
Chimerix (NASDAQ:CMRX) announced a live conference call scheduled for March 1, 2022, at 8:30 a.m. ET to review its financial results for Q4 and the full year ending December 31, 2021. The call will provide insights into the company’s progress alongside a business overview. Chimerix, focused on developing therapies for deadly diseases, recently gained FDA approval for TEMBEXA, a smallpox treatment, and is advancing two clinical programs: ONC201 for glioma and DSTAT for acute myeloid leukemia.
Chimerix (NASDAQ:CMRX) will have Mike Andriole, Chief Business and Financial Officer, present a corporate overview at the B. Riley Virtual Oncology Conference on January 27, 2022, at 3:00 p.m. ET. An audio webcast of the presentation will be accessible on the Investor Relations section of Chimerix's website for about 90 days following the event.
Chimerix is dedicated to developing medicines for deadly diseases, notably having received FDA approval for TEMBEXA for smallpox treatment. The company is also advancing ONC201 for recurrent glioma and DSTAT for acute myeloid leukemia.
Chimerix (NASDAQ:CMRX) announced the publication of a peer-reviewed article on its Phase 2 study of ONC201 in neuroendocrine tumors, including pheochromocytoma-paraganglioma and desmoplastic small round cell tumor. The study involved 30 patients and showed that 50% of paraganglioma patients receiving ONC201 once weekly had a partial response, with no decline in performance status for 93% of participants. This data supports further investigation into ONC201's efficacy for neuroendocrine tumors, alongside its primary focus on recurrent H3 K27M-mutant diffuse midline glioma.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced that its management team, including CEO Mike Sherman and CFO Mike Andriole, will participate in a pre-recorded fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The session will be available on January 10, 2022, at 7:00 a.m. ET. An audio webcast of the event will be accessible on their Investor Relations website for about 90 days. Chimerix focuses on developing medicines to improve patient lives, with recent FDA approval of TEMBEXA for smallpox treatment.
Chimerix (NASDAQ:CMRX) announced positive data from a 50-patient efficacy analysis of ONC201 for treating recurrent H3 K27M-mutant diffuse midline glioma. The data will be presented on November 20, 2021, during the Society for Neuro-Oncology Annual Meeting. Key highlights include a 20% overall response rate and a median duration of response of 11.2 months. The FDA has granted ONC201 several designations to expedite its development. A conference call to discuss the results is scheduled for November 22, 2021.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET. This pre-recorded presentation will be accessible via an audio webcast on Chimerix's Investor Relations website, where it will be archived for 90 days. Chimerix focuses on developing medicines for patients with life-threatening diseases, having recently received FDA approval for TEMBEXA to treat smallpox and advancing clinical-stage programs for ONC201 and dociparstat sodium in oncology.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced its data presentations at the Society for Neuro-Oncology Annual Meeting 2021 in Boston from November 19-21, 2021. The late-breaking plenary oral presentation titled "Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients" will occur on November 20, 2021. Additional presentations will cover ONC201's activity and safety in various glioma cases. Chimerix is committed to developing treatments for deadly diseases and recently received FDA approval for TEMBEXA to treat smallpox.
Chimerix (NASDAQ:CMRX) announced positive topline results from ONC201 for treating recurrent H3 K27M-mutant glioma, showing a 20% overall response rate. Additionally, the FDA published a benefit-risk assessment of TEMBEXA for smallpox. In the third quarter of 2021, Chimerix reported a net loss of $18.6 million and revenues of $0.1 million, a decline from $1.6 million the previous year. R&D expenses rose to $13.8 million, driven by an expanded pipeline following the Oncoceutics acquisition. The company has $125 million in capital to fund operations.
Chimerix (NASDAQ:CMRX) announced positive topline data for ONC201, reporting a 20.0% objective response rate for recurrent H3 K27M-mutant glioma patients. The median duration of response was 11.2 months, and the median time to response was 8.3 months. These results, highlighted by leading oncologists, showcase the treatment's potential for patients lacking effective options. Chimerix plans to present further findings at the Society for Neuro-Oncology Annual Meeting on November 20, 2021. ONC201 has received Fast Track and Rare Pediatric Disease Designations from the FDA.
DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, at 9:40 a.m. ET. An audio webcast will be accessible on the Investor Relations section of Chimerix's website, where it will be archived for about 90 days. Chimerix is focused on developing innovative medicines for serious diseases. The company recently received FDA approval for TEMBEXA, targeting smallpox, and is advancing clinical programs for ONC201 and dociparstat sodium.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
What does Chimerix, Inc. do?
What are Chimerix's leading compounds?
What stages are Chimerix's clinical trials in?
How is Chimerix financially positioned?
What is the significance of the ONC201 Phase 3 ACTION trial?
What kind of partnerships does Chimerix have?
Where is Chimerix based?
How does Chimerix generate revenue?
What is unique about Chimerix’s lipid technology?
What is Chimerix's mission?
